<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>383</serviceExecutionTime><Drug id="57794"><DrugName>AZD-1480</DrugName><DrugSynonyms><Name><Value>AZD-1480</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Jak tyrosine kinase inhibitors (cancer), AstraZeneca</Value></Name></DrugSynonyms><CompanyOriginator id="14190">AstraZeneca plc</CompanyOriginator><CompaniesSecondary><Company id="14190">AstraZeneca plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="57794" type="Drug"><TargetEntity id="458112" type="siDrug">AZD-1480</TargetEntity></SourceEntity><SourceEntity id="14190" type="Company"><TargetEntity id="4295894341" type="organizationId">AstraZeneca PLC</TargetEntity></SourceEntity><SourceEntity id="273" type="ciIndication"><TargetEntity id="10028576" type="MEDDRA"></TargetEntity><TargetEntity id="D009196" type="MeSH"></TargetEntity><TargetEntity id="-1904668786" type="omicsDisease"></TargetEntity><TargetEntity id="1247" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3562" type="Action"><TargetEntity id="1506" type="Mechanism">Jak1 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="3564" type="Action"><TargetEntity id="1505" type="Mechanism">Jak2 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01184" type="ciTarget"><TargetEntity id="137155796837163" type="siTarget">Tyrosine-protein kinase JAK1</TargetEntity><TargetEntity id="431" type="omicsTarget"></TargetEntity></SourceEntity><SourceEntity id="PTGT-01185" type="ciTarget"><TargetEntity id="189436773537173" type="siTarget">Tyrosine-protein kinase JAK2</TargetEntity><TargetEntity id="432" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="273">Myeloproliferative disorder</Indication><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="3562">Jak1 tyrosine kinase inhibitor</Action><Action id="3564">Jak2 tyrosine kinase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-28T06:06:25.000Z</LastModificationDate><ChangeDateLast>2017-05-23T00:00:00.000Z</ChangeDateLast><AddedDate>2007-08-06T16:42:14.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt; was developing the JAK 1/2 inhibitor AZD-1480  for the potential oral  capsule treatment of cancer, including solid tumors, and myeloproliferative disorders [&lt;ulink linkID="816181" linkType="Reference"&gt;816181&lt;/ulink&gt;], [&lt;ulink linkID="1017204" linkType="Reference"&gt;1017204&lt;/ulink&gt;]. In May 2009, a phase I/II study began in subjects with myeloproliferative disease [&lt;ulink linkID="1017204" linkType="Reference"&gt;1017204&lt;/ulink&gt;]. In April 2010, a phase I study in patients with solid tumors was initiated [&lt;ulink linkID="1096813" linkType="Reference"&gt;1096813&lt;/ulink&gt;]; in November 2012, data were presented [&lt;ulink linkID="1336657" linkType="Reference"&gt;1336657&lt;/ulink&gt;]. However, by December 2012, development had been terminated [&lt;ulink linkID="1364924" linkType="Reference"&gt;1364924&lt;/ulink&gt;]. By August 2014, the drug was available for partnering with academics for preclinical development in other indications or as a research tool through AstraZeneca's Open Innovation program [&lt;ulink linkID="1586754" linkType="Reference"&gt;1586754&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumors&lt;/subtitle&gt;In April 2010, a non-randomized, open-label phase I study (&lt;ulink linkID="65978" linkType="Protocol"&gt;NCT01112397&lt;/ulink&gt;; D1060C00002) was initiated in patients with solid tumors (expected n = 80) in the US, to assess the safety and pharmacokinetics of AZD-1480 alone or in combination with docetaxel. The study was expected to be complete by September 2012. By November 2011, the protocol had been amended to assess AZD-1480 only as a monotherapy [&lt;ulink linkID="1096813" linkType="Reference"&gt;1096813&lt;/ulink&gt;]. In November 2012, data were presented at the 24th EORTC-NCI-AACR symposium in Dublin, Ireland. In patients treated with AZD-1480 (35 mg, bid), &amp;gt; 90% pathway suppression was observed 2 h post dose. A rapid absorption of AZD-1480 was observed. The clearance appeared to be low to moderate, and accumulation of AZD-1480 was not observed [&lt;ulink linkID="1336657" linkType="Reference"&gt;1336657&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Myeloproliferative disorder&lt;/subtitle&gt;In May 2009, a phase I/II open-label, single group assignment study (&lt;ulink linkID="56924" linkType="Protocol"&gt;NCT00910728&lt;/ulink&gt;; D1060C00001) was initiated to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AZD-1480 in patients  (n = 80) with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis. Subjects would receive  AZD-1480 capsules po at 2.5, 10 and 100 mg. Primary outcome measures would include a general assessment of adverse events, pulmonary function tests, and a chest CT scan, as well as pharmacokinetics. The trial was expected to be completed in November 2010. However, in November 2011,  the trial was ongoing; by that time, enrollment had been completed [&lt;ulink linkID="1017204" linkType="Reference"&gt;1017204&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2016, preclinical data were presented at the 107th AACR Annual Meeting in New Orleans, LA, USA. In mouse PTEN-deficient prostate cancer, AZD-1480 reduced tumor growth and tumor vascularity, exhibited potent anti-proliferative and pro-apoptotic activity and inhibited STAT3 phosphorylation. In mouse PTEN/P53-deficient prostate cancer, AZD-1480 showed improvement in overall survival  and progression-free survival , and reduction in tumors regression [&lt;ulink linkID="1755866" linkType="Reference"&gt;1755866&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, preclinical data were presented at the 24th EORTC-NCI-AACR symposium in Dublin, Ireland. In multiple solid tumor xenografts models, weekly doses of AZD1480 (30 mg/kg qd or bid) was found to be efficacious. A correlation was observed between the clinical tumor and surrogate tissue pSTAT3 inhibition, approximately 2 h post dose [&lt;ulink linkID="1336657" linkType="Reference"&gt;1336657&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2012, preclinical data were presented at the AACR annual meeting in Chicago, IL. AZD-1480 was evaluated in a preclinical study to determine its effect on lung tumors induced by activating EGFR mutations. Transgenic mice expressing the delE748-A752 mutant of mouse epidermal growth factor receptor (EGFR) were treated with oral AZD-1480 (30 mg/kg/day; n = 13) or vehicle alone (n = 13) from 7 weeks of age until they died. Data showed that the median overall survival in the AZD-1480-treated group (217 days) was significantly longer than that in the control group (106 days); after initiation of treatment at week 7, the body weight of mice in the control group was also significantly lower than that in the AZD-1480 group [&lt;ulink linkID="1275188" linkType="Reference"&gt;1275188&lt;/ulink&gt;]. Futher data presented from a preclinical study of metastatic pediatric neuroblastoma, Ewing sarcoma and rhabdomyosarcoma showed that in vitro, AZD-1480 treatment inhibited IL-6 induced and endogenous phosphorylation of STAT3 and decreased cell viability in all tested cell lines. AZD-1480 also induced cell growth inhibition, G2 arrest and apoptosis in a dose-dependent manner, and inhibited the expression of STAT3 downstream targets in a cell-specific and dose-dependent manner. In vivo, AZD-1480 delayed tumor growth in all tested cell lines, and increased survival particularly in mice bearing KCNR and SY5Y neuroblastoma xenografts [&lt;ulink linkID="1275250" linkType="Reference"&gt;1275250&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2010, preclinical data were presented at the 240th ACS meeting in Boston, MA. AZD-1480 inhibited autophosphorylation of TrkA in MCF10A breast cancer cells (56-fold selectivity over aurora A). It inhibited phosphorylation of STAT5 in TEL-JAK2 leukemia cells (IC50 = 59 nM) and proliferation of these cells (GI50 = 60 nM). In a human megakaryoblastic cell line dependent on JAK2 activity, AZD-1480 caused phosphorylation of STAT3 and STAT5 at low nM concentrations, and inhibited proliferation of human JAK2 V617F progenitor cells ex vivo. In vivo, in a mouse allograft model implanted with JAK2-TEL cells, po dosing up to 30 mg/kg led to dose-dependent inhibition of the STAT5 signal 2 h post-dose. In an adoptive transfer mouse model of myeloproliferative neoplasia, 10 mg/kg AZD-1480 bid lead to normalization of white blood cells and hematocrit, and reduced spleen size at day 28. Good pharmacokinetic data were seen in  dog and mouse, with no CYP inhibition liabilities  [&lt;ulink linkID="1122340" linkType="Reference"&gt;1122340&lt;/ulink&gt;], [&lt;ulink linkID="1126408" linkType="Reference"&gt;1126408&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2009, preclinical data were presented at the 100th AACR meeting in Denver, CO, showing that  AZD-1480 blocked cell proliferation and induced apoptosis in myeloma cell lines at low micromolar concentrations. AZD-1480 also blocked JAK2/STAT3 signaling in myeloma cells cultured alone or with bone marrow stromal cells [&lt;ulink linkID="997332" linkType="Reference"&gt;997332&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2008, preclinical data  were presented at the 13th DDT in Boston, MA.  AZD-1480  was a 260-pM inhibitor 14-fold selective for JAK2 over JAK3. It blocked STAT5 activation and proliferation, inhibited proliferation and induced apoptosis in the SET2 cell line. In a mouse model, AZD-1480 reduced proliferation of stem cells transfected with the JAK2 mutant [&lt;ulink linkID="935916" linkType="Reference"&gt;935916&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="273">Myeloproliferative disorder</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1364924" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1364924" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="273">Myeloproliferative disorder</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1364924" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2010-04-27T00:00:00.000Z</StatusDate><Source id="1096813" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="273">Myeloproliferative disorder</Indication><StatusDate>2009-05-31T00:00:00.000Z</StatusDate><Source id="1017204" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="273">Myeloproliferative disorder</Indication><StatusDate>2009-05-31T00:00:00.000Z</StatusDate><Source id="1017204" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14190">AstraZeneca plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2007-07-26T00:00:00.000Z</StatusDate><Source id="816181" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01184"><Name>Jak1 tyrosine kinase</Name><SwissprotNumbers><Swissprot>O12990</Swissprot><Swissprot>P23458</Swissprot><Swissprot>P52332</Swissprot><Swissprot>Q09178</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01185"><Name>Jak2 tyrosine kinase</Name><SwissprotNumbers><Swissprot>O60674</Swissprot><Swissprot>Q62120</Swissprot><Swissprot>Q62689</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>Cc1cc(n[nH]1)Nc2c(cnc(n2)N[C@@H](C)c3ncc(cn3)F)Cl</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="2675081" number="WO-2014018660" title="Functional genomics screening platform for head and neck cancer"/><PatentFamily id="2713678" number="WO-2014053852" title="Treatment of cancer"/><PatentFamily id="2811059" number="WO-2014161046" title="Methods of treating diseases characterized by excessive Wnt signalling"/><PatentFamily id="2846385" number="WO-2014199166" title="Method of increasing viral growth rate and/or titre in cells"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sorrento Therapeutics Inc" id="1048574"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Melbourne" id="20620"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Pittsburgh" id="20659"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Walter and Eliza Hall Institute of Medical Research" id="21082"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="St Andrews University" id="25009"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>